Collaboration and License Agreements (Details) $ in Thousands, shares in Millions		1 Months Ended	3 Months Ended								12 Months Ended						18 Months Ended	47 Months Ended
	Dec. 31, 2015 USD ($)	Feb. 28, 2015 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2015 USD ($) item shares	Dec. 31, 2014 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2012 USD ($)	Dec. 31, 2011	Dec. 31, 2015 USD ($)
Collaboration revenues:
Product revenue			$ 17,810	$ 8,666	$ 19,305	$ 2,722	$ 4,747	$ 4,714	$ 5,690	$ 4,812	$ 48,503	$ 19,963		$ 16,701
Research and development revenue
Regulatory and commercial milestones											20,000	12,000
Amortization of upfront payments											9,014	3,719		3,979
Research and development services (FTEs) and external costs											12,133	16,568		14,785
Total research and development revenue											41,147	32,287		18,764
Total collaboration revenue			22,393	$ 13,795	$ 44,900	$ 8,562	$ 21,179	$ 9,336	$ 10,950	$ 10,785	89,650	52,250		35,465
Operating expenses:
Research and Development Expense											3,031	17,898		26,034
General and Administrative Expense											1,513	951		1,004
Total Operating expenses											$ 4,544	18,849		27,038
Number of shares sold | shares											4.7
Aggregate purchase price of shares sold											$ 75,000
Premium paid											13,600
2003 Sandoz Collaboration
Collaboration revenues:
Product revenue											5,063	19,963		16,701
Research and development revenue
Research and development services (FTEs) and external costs											789	1,043		3,040
Total research and development revenue											789	1,043		3,040
Total collaboration revenue											5,852	21,006		19,741
Operating expenses:
Research and Development Expense											324	341		802
General and Administrative Expense											344	125
Total Operating expenses											$ 668	466		802
Percentage of contractual profits earned under collaborative arrangement																	45.00%
Percentage of royalty for net sales up to pre-defined sales threshold																		10.00%
Percentage of royalty for net sales above pre-defined sales threshold																		12.00%
Percentage of royalty based on contractually defined profits on sales				50.00%
Maximum percentage of reduction of profit-share, royalty and milestone payments from Sandoz at each quarter				50.00%
Reduction in product revenue due to netting of shared development and other expenses	$ 1,800												$ 2,200		$ 3,800
Decrease in amount of adjustment related to product revenue																$ 2,100
Number of significant deliverables identified in arrangement | item											2
Second Sandoz Collaboration Agreement
Collaboration revenues:
Product revenue											$ 43,440
Research and development revenue
Regulatory and commercial milestones											20,000
Amortization of upfront payments												480		1,128
Research and development services (FTEs) and external costs											2,861	2,452		715
Total research and development revenue											22,861	2,932		1,843
Total collaboration revenue											66,301	2,932		1,843
Operating expenses:
Research and Development Expense											856	920		2,525
General and Administrative Expense											206	299		511
Total Operating expenses											$ 1,062	1,219		3,036
Percentage of royalty based on contractually defined profits on sales											50.00%
Profits recorded on sales			43,400								$ 52,500
Collaborative Arrangement, Legal Expenses											9,100
Second Sandoz Collaboration Agreement | Maximum
Operating expenses:
Milestone payments possible per agreement	120,000		120,000								120,000							$ 120,000
Commercial milestone payments	10,000		10,000								10,000							10,000
Regulatory milestone payment earned											$ 10,000
Second Sandoz Collaboration Agreement | Novartis Pharma AG
Operating expenses:
Percentage of contractual profits earned under collaborative arrangement											50.00%
Baxter Agreement
Operating expenses:
Remaining payment obligation	$ 0		$ 0								$ 0							$ 0
Baxalta Agreement
Research and development revenue
Regulatory and commercial milestones												12,000
Amortization of upfront payments											9,014	3,239		2,851
Research and development services (FTEs) and external costs											8,483	13,073		11,030
Total research and development revenue											17,497	28,312		13,881
Total collaboration revenue											17,497	28,312		13,881
Operating expenses:
Research and Development Expense											1,851	16,637		22,707
General and Administrative Expense											963	527		493
Total Operating expenses											2,814	$ 17,164		$ 23,200
Upfront payment paid by Baxter to the company											33,000
Option payments agreed to be paid by Baxter with respect to additional product candidates											12,000
Option payment which the entity is no longer eligible to receive											$ 7,000
Baxalta Agreement | Accounting Standards Update 2009 to 2013 Member
Operating expenses:
Number of significant deliverables identified in arrangement | item											7
Total arrangement consideration		$ 61,000									$ 61,000
Portion of revised arrangement consideration reallocated to the remaining deliverables		40,000									61,000
Portion of revised arrangement consideration allocated to the first initial product license as a result of termination of product		39,600									10,300
Portion of revised arrangement consideration allocated to each of the three additional product licenses as a result of termination of product		400									10,300
Portion of revised arrangement consideration allocated to the second initial product license as a result of termination of product											9,400
Portion of revised arrangement consideration allocated to the joint steering committee unit of accounting as a result of termination of product											$ 114,000
Decrease in portion of revised arrangement consideration reallocated to the remaining deliverables		$ 40,000
Estimate performance period for the joint steering committee											6 years
Number of follow-on biologic products for development and product licenses | item											2
Number of additional follow-on biologic products for development and product licenses | item											4
Number of additional follow-on biologic products for research and development services | item											4
Deferred revenue											$ 22,000
Deferred revenue included in current liabilities											9,800
Deferred revenue included in non-current liabilities											12,200
Baxalta Agreement | Maximum
Operating expenses:
Aggregate regulatory milestone to be paid by Baxter											$ 50,000